SPPI - Spectrum Pharmaceuticals, Inc.
| Previous Close | 18.86 |
| Open | 18.77 |
| Bid | 17.80 x 1100 |
| Ask | 18.90 x 100 |
| Day's Range | 18.18 - 18.77 |
| 52 Week Range | 5.47 - 23.50 |
| Volume | 703,708 |
| Avg. Volume | 1,574,674 |
| Market Cap | 1.878B |
| Beta | 2.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.07 |
| Earnings Date | Mar 7, 2017 - Mar 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2012-12-18 |
| 1y Target Est | 29.25 |
- Business Wire•5 days ago
Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago
Spectrum Pharmaceuticals , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced a poster presentation of data from preclinical and clinical studies evaluating poziotinib in HER2 exon 20 mutations in non-small cell lung cancer and summarizing a dataset of the prevalence of HER2 exon 20 across solid tumors ...
- Market Exclusive•5 days ago
Here’s What Happened Last Week In Biotech
It was a busy week last week in the biotechnology space, with a whole host of companies putting out updates on their respective operations (primarily rooted in development pipelines) and these updates subsequently injecting a considerable amount of volatility into the markets on their release. Here’s a look at some of the biggest movers, what […] The post Here’s What Happened Last Week In Biotech appeared first on Market Exclusive.
- Motley Fool•8 days ago
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these red-hot biotech stocks keep the momentum going?
- ACCESSWIRE•10 days ago
Wired News – Spectrum Pharma Reported Update Data from MD Anderson’s Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients
Stock Monitor: Moleculin Biotech Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors.com has just released a free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI ...
- Zacks•11 days ago
Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis
The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.
- Zacks•11 days ago
Spectrum Pharma Stock Up on Positive Lung Cancer Study Data
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
- Zacks•11 days ago
Implied Volatility Surging for Spectrum Pharmaceuticals (SPPI) Stock Options
Spectrum Pharmaceuticals (SPPI) needs investors to pay close attention to the stock based on moves in the options market lately.
- ACCESSWIRE•11 days ago
Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Tandem Diabetes Care
NEW YORK, NY / ACCESSWIRE / April 11, 2018 / Spectrum Pharmaceuticals and Tandem Diabetes Care both exploded in Tuesday trading. Spectrum headed higher after announcing positive data from a phase 2 trial ...
- Motley Fool•12 days ago
Why Sprint, Spectrum Pharmaceuticals, and NVIDIA Jumped Today
Find out what helped send the market higher.
- Benzinga•12 days ago
Benzinga's Top Analyst Calls From April 10, 2018
Maxim raises BeiGene Ltd (NASDAQ: BGNE ) price target from $160 to $200; Says the company continues to advance its clinical pipeline with multiple catalysts ahead and a strong balance sheet with runway ...
- Motley Fool•12 days ago
Why Spectrum Pharmaceuticals, Inc. Is Soaring Today
Traders cheer after the company shares additional data from an important phase 2 trial.
- Business Wire•12 days ago
Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients
Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that updated poziotinib Phase 2 data in MD Anderson’s EGFR Exon 20 Mutant Non-Small Cell Lung Cancer study are available, based on longer follow-up.
- Investopedia•18 days ago
Top 4 Small-Cap Stocks for 2018
Looking at growth outlooks and price targets, these four small-cap stocks could be stellar for 2018.
- ACCESSWIRE•19 days ago
Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Insmed
NEW YORK, NY / ACCESSWIRE / April 3, 2018 / U.S. equities fell sharply on Monday, weighed down by losses in the technology sector and global trade concerns. The Dow Jones Industrial Average decreased 1.90 ...
- Business Wire•19 days ago
Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 10th
Spectrum Pharmaceuticals , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the H.C.
- Zacks•last month
Is the Options Market Predicting a Spike in Spectrum Pharmaceuticals (SPPI) Stock?
Surging implied volatility makes Spectrum Pharmaceuticals (SPPI) stock lucrative to the option traders.
- Investopedia•last month
Top 4 Small-Cap Stocks for 2018
Looking at growth outlooks and price targets, these four small-cap stocks could be stellar for 2018.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of SPPI earnings conference call or presentation 6-Mar-18 9:30pm GMT
Q4 2017 Spectrum Pharmaceuticals Inc Earnings Call
Motley Fool•2 months agoWhy Kroger, AeroVironment, and Spectrum Pharmaceuticals Slumped Today
In a mixed market, these stocks fell. Here's why.
- Motley Fool•2 months ago
Here's Why Spectrum Pharmaceuticals, Inc. Is Slipping Today
A revenue miss and less-than-encouraging news for poziotinib upset investors.
- Zacks•2 months ago
Spectrum (SPPI) Q4 Loss Widens Y/Y, Sales Miss, Stock Falls
Spectrum (SPPI) reports narrower-than-expected loss in the fourth quarter, while it misses on revenues. Rolontis successful in phase III study.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Spectrum Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / U.S. markets had a topsy-turvy day as concerns of a potential trade war, a result of tariffs proposed by President Donald Trump, continue to worry investors. ...
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Portola Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Spectrum Pharmaceuticals and Portola Pharmaceuticals were two of the most active biotech stocks in the market on Tuesday. Spectrum reported its fourth quarter ...
- Business Wire•2 months ago
Spectrum Pharmaceuticals to Present Corporate Update at the Cowen and Company 38th Annual Health Care Conference on March 13th
Spectrum Pharmaceuticals , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Cowen and Company 38th Annual Health Care Conference being held at The Boston Marriott Copley Place in ...
